A systematic review and meta-analysis finds that weight-loss interventions are associated with decreased psoriasis severity ...

A large US claims analysis links out-of-pocket medication costs with adherence and discontinuation patterns among patients ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.

Oruka analysis: ultra-durable psoriasis biologics ORKA-001/002 aim for 1–3 doses/yr with strong efficacy; liquid balance ...

Immune-mediated diseases specialist Alumis has announced positive top-line results from its Phase III ONWARD1 and ONWARD2 ...

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.